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Abstract
The Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) have recently
been the focus of tremendous advances in basic knowledge of disease pathophysiology following the
recognition of mutations in JAK2 and MPL. These discoveries also led to refinement of the criteria
employed for diagnosis. The prognostic roles of the JAK2 V617F mutation and of leukocytosis as
independent risk factors for thrombosis, which represents the leading cause of death in patients with
polycythemia vera and essential thrombocythemia, are supported by retrospective studies. A new
risk stratification approach to the patient with primary myelofibrosis allows clinicians to distinguish
categories of patients with significantly different expected survival. Finally, new drugs are currently
being tested for MPNs, and molecular discoveries could ultimately lead to the development of a
specific targeted therapy. Overall, significant advances in diagnosis, prognostication, and treatment
have taken place in the last couple of years in the field of MPNs.
Introduction and context
The Philadelphia chromosome-negative chronic
myeloproliferative neoplasms (MPNs) include poly-
cythemia vera (PV), essential thrombocythemia (ET),
and primary myelofibrosis (PMF) [1]. PV and ET are
relatively indolent disorders that result in a modest
reduction of survival, usually after the first decade from
the time of diagnosis; PMF, on the other hand, has a
more severe course and a median survival of about
5 years, although some patients experience survival of
longer than 10 years. The course of PV and ET is marked
by an excess of arterial and venous thrombosis, which
represent the principal cause of morbidity and mortal-
ity; major hemorrhage, evolution to post-polycythemia
vera/post-essential thrombocythemia myelofibrosis
(PPV/PET-MF), and transformation to acute myeloid
leukemia (AML) also contribute to reduced survival.
Causes of death in patients with PMF are related to the
consequences of myeloproliferation or bone marrow
failure, vascular events, infections, and transformation
to AML.
In 2005, a point mutation in exon 14 of the Janus kinase
2 gene (JAK2 V617F) was discovered in the majority of
patients with PV and in about 60% of those with ET or
PMF [2-5]. Additional mutations in exon 12 of JAK2 [6]
and at codon 515 of the myeloproliferative leukemia
virus oncogene (MPL) [7] were reported in a minority of
patients with PV or in 5% and 10% of patients with ET
and PMF, respectively. These mutant alleles all result in a
gain of function due to constitutive activation of tyrosine
kinase-dependent cellular signaling pathways, particu-
larly the JAK-signal transducer and activator of trans-
cription (JAK-STAT) pathway [8]. During the search for
additional genetic abnormalities in MPNs with the use of
high-resolution SNP (single-nucleotide polymorphism)
analysis, a region of acquired UPD (uniparental disomy)
was identified at chr4q24, where the TET2 gene maps [9].
Abnormalities in TET2 are believed to antedate the
acquisition of JAK2 V617F point mutation in most, but
not all, cases [9,10]. The precise function of TET2 is
unknown, but the gene might behave as a bona fide
oncosuppressor. However, it was soon shown that
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patients and are shared by other myeloid malignances, in
particular myelodysplastic syndromes and chronic
myelomonocytic leukemia [11-14].
Clustering of myeloproliferative disorders in some
families has been recognized for some time. Further-
more, a recent epidemiologic study from Sweden found
that the risk of developing an MPN is up to seven-fold
greater in first-degree relatives of MPN patients than in
the general population [15]. The genetic predisposition
to MPN, particularly but not exclusively among patients
harboring the V617F mutation, has been attributed to a
specifichaplotype,called46/1orGGCC,thatislocatedat
chromosome 9 and includes the JAK2 gene itself [16-19].
Overall, this information has significantly advanced our
understanding of the pathophysiology of MPN and, by
pointing to mutated kinases as a common mechanism in
these disorders, has suggested that tyrosine kinases might
represent a valid target for therapy, as exemplified by the
efficacy of imatinib and second-generation tyrosine
kinase inhibitors in chronic myelogenous leukemia.
Recent advances
Diagnosis
One seminal advance has been the revision [20] of the
criteria employed for diagnosis that was promoted by
the demonstration of an almost universal association of
the JAK2 V617F mutation with PV and an association in
about 60% of patients with ET or PMF. According to the
2008 World Health Organization (WHO) classification
[21], the presence of any of these mutations constitutes a
majorcriterionfordiagnosis.However,thediagnosisofET
or PMF still requires expert evaluation of bone marrow
histopathology in order to identify specific morphologic
patterns associated with either disease. Another clinical
settinginwhichdiagnosishasbeensignificantlyimproved
is represented by the splancnic vein thromboses that have
been found to be associated with the JAK2 V617F
mutation in up to half of cases [22], thus establishing an
MPN as the commonest underlying cause [23]. Finally, a
consensus statement from the International Working
Group for Myelofibrosis Research and Treatment (IWG-
MRT) proposed uniform criteria for diagnosing the
evolution of PV or ET to PPV/PET-MF [24]. Overall,
these molecular and clinical advances have made the
diagnostic work-up of the commonest MPN more effec-
tive and reproducible, a key premise for clinical studies
and for the design of trials of innovative drugs.
Prognosis
The only criteria currently used for risk stratification of
PV or ET patients are older age and previous history of
thrombosis. However, several studies, supported by
meta-analyses, have documented the association of the
JAK2 V617F mutation with an increased risk of arterial
and venous thrombosis in patients with ET (hazard ratio
1.8- to 2.0-fold greater than that of JAK2 unmutated ET
patients) [25], particularly if the mutation is harbored in
a homozygous status (i.e., both alleles are mutated) [26].
One study reported that patients with PV who have a
high ‘allele burden’ (i.e., a prevalence of mutated versus
normal alleles) are at greater risk for thrombosis [27]. It
is also possible that the accumulation of mutated alleles
in PV or ET accompanies transformation to PPV/PET-MF
[26,28]. On the contrary, PMF patients with lower JAK2
V617F allele burden are at increased risk of death
[29,30]. Thus, evidence that, in addition to diagnostic
relevance, a JAK2 V617F mutated status or a high burden
of mutated allele or both have prognostic correlates is
being accumulated [31]. On the other hand, TET2
mutations have not been associated yet with clinical
endpoints [32]. Finally, while it is accepted that the
occurrence of thrombosis in PV or ET is not directly
linked to raised hematocrit or platelet count, leuko-
cytosis has recently been associated with increased risk
of major vascular events and eventually could represent
a major target of cytoreductive therapy [33].
Identification of PMF patients with expected shorter
survival is pivotal for appropriate decision making in
regard to hematopoietic stem cell transplantation, which
offers the only chance of cure but is still burdened by
significant mortality and morbidity. A new and highly
discriminatory prognostic system has been devised by
the IWG-MRT on the basis of a study of 1054 patients
[34]. Variables predicting shortened survival were an age
of greater than 65 years, presence of constitutional
symptoms, hemoglobin level of less than 100 g/L, leuko-
cyte count of greater than 25 × 10
9/L, and percentage of
circulating blast cells of 1% or greater. When these
variables were used, four risk groups that differed
significantly in median survival, ranging from 135 to
95, 48, and 27 months, were delineated [34]. These five
variables maintained their impact on survival when
analyzed as time-dependent covariates during the
follow-up of PMF patients, whether younger or older
than 65 years [35]. Therefore, prognostic assessment of
patients with PMF can be performed anytime during
their clinical course by using these criteria and may guide
treatment decision.
Treatment
The central role that alterations in the JAK-STAT pathway
play in clinical manifestations of MPN has made
targeting JAK2 an appealing therapeutic goal [36,37].
A number of drugs exhibiting differential inhibitory
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other receptor kinases, such as FGFR (fibroblast growth
factor receptor), PDGFR (platelet-derived growth factor
receptor), and FLT3 (FMS-like tyrosine kinase 3), are
currently in clinical development. Most experience has
been in patients with myelofibrosis in phase I/II trials
employing INCB018424 (a potent and selective inhibi-
tor of JAK1 and JAK2), TG101348 (a structure-based
drug designed to inhibit JAK2 with great selectivity),
CEP-701 (a multikinase inhibitor), and XL019 (a
selective JAK2 inhibitor whose clinical development
has been halted because of neurotoxicity). With some
differences, the first results available indicated substan-
tial activity against enlarged spleen and systemic
symptoms, whereas the effects on the mutational burden
were more variable [38].
While the use of JAK2 inhibitors is ongoing, other
important trials have been completed in the last two
years. Lenalidomide, an immunomodulating agent, was
reported to produce a 20-30% response rate in anemia
and splenomegaly, and overall this is similar to the
experience with thalidomide and prednisone; myelo-
toxicity was common [39]. Another study indicated that
the combination of lenalidomide and prednisone might
be better tolerated, responses were more durable, and a
significant reduction of JAK2 V617F allele burden was
reported [40]. However, response rate and quality of
response were impressive in myelofibrotic patients
harboring the del(5)q abnormality, and lenalidomide
should be considered as first-line therapy in this specific
subset of patients [41]. A third thalidomide analog,
pomalidomide, has been evaluated in a phase II rando-
mized, multicenter, double-blind study. The drug was
effective for treatment of anemia in up to 36% of the
patients, with minimal hematological and extra-
hematological toxicity. No changes in JAK2 V617F
allele burden were observed [42]. Similar results (33%
for hepatosplenomegaly and 38% for transfusion-
dependent anemia) were reported in a phase II trial
with tipifarnib, a farnesyltransferase inhibitor [43].
The role of epigenetic abnormalities in the pathogenesis
of MPNs represents a novel field of research [44]. In this
regard, a recent paper reported that JAK2 possesses a
nuclear activity and regulates the phosphorylation of
histone H3 [45], thereby affecting the expression of
target genes, including putative oncogenes such as
lmo2. Furthermore, TET1, another member of the TET
family, has been shown to catalyze the conversion of
5-methylcytosine to 5-hydroxymethylcytosine, possibly
intervening in the regulation of transcriptional activity
[46]. These observations may have therapeutic relevance.
However, two similar but independent trials failed to
observe any favorable effect of 5-azacytidine in myelofi-
brosis [47,48]. On the contrary, ITF2387, a histone
deacethylase inhibitor, was reported to have significant
activity in the control of hematological abnormalities
and systemic symptoms in patients with PV or ET [49].
Interferon (IFN) has been used sporadically in PV and ET
for some time. In France, a phase II study of pegylated
IFN-a-2a in PV included 40 patients. Eighty-nine percent
of the patients presented a mean decrease of the V617
allele of 44%, with complete disappearance of the V617F
allele in one patient. The results would confirm the
hypothesis that IFN-a preferentially targets the malig-
nant clone in PV [50].
The availability of novel drugs calls for the need to
have standardized criteria for assessing response to
therapy. While response criteria in patients with PMF
were published several years ago [51,52], criteria of
response to treatment in PV and ET patients have
been published only recently following a European
consensus conference [53].
Implications for clinical practice
Testing of the JAK2 V617F and, more selectively, MPL
W515L/K/A or JAK2 exon 12 mutational statuses has
made the diagnosis of MPN more precise than ever
before. Therefore, genotyping for those mutations is
mandatory in the work-up of a patient suspected of
having an MPN. Nowadays, diagnoses are expected to
strictly fulfill the 2008 WHO criteria. Also, the IWG-MRT
criteria for the diagnosis of PPV/PET-MF should be
routinely adopted in clinical practice. Genotype-pheno-
type associations have been identified; however, quanti-
tative methods for measuring JAK2 V617F allele burden
are specialized tools that are still best used within clinical
trials. After all, the decision to treat ET or PV patients
based on the presence of the mutation, a high mutated
allele burden, or leukocytosis as surrogate markers of
increased thrombotic risk deserves prospective valida-
tion and cannot be routinely recommended outside
clinical trials.
It is now time to start assuming that the clinical course of
MPNs may be improved by therapy and the disease
possibly cured. Molecular discoveries have made the
development of JAK2 tyrosine kinase inhibitors an
attractive therapeutic goal, and molecules that inhibit
JAK2 kinase are being evaluated with measurable results
in the clinical setting. Actually, the rapid and marked
improvement in splenomegaly and quality of life
observed in myelofibrotic patients treated with
INCB018424 or TG101348 has never been seen before
with any drug and per se justify enthusiasm. Novel
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more effective than thalidomide in the setting of
myelofibrosis. Drugs acting on epigenetic gene regula-
tion, either alone or eventually in combination, hold
some promise. Finally, while it is noteworthy that IFN
proved able to induce clonal remission in patients with
PV, larger studies are needed to define the proportion of
patients achieving such a goal as well as the long-term
treatment tolerability of pegylated formulations. How-
ever, whether aiming at molecular remission is a
valuable clinical endpoint for the long-term manage-
ment of PV or ET, as it might be for myelofibrosis, still
requires demonstration.
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